Can a monoclonal antibody improve outcomes in ulcerative colitis?

Two phase III trials have demonstrated that the monoclonal antibody risankizumab may be safe and effective as both induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.

In the induction trial, published in JAMA, researchers assigned 975 patients to receive 1,200 milligrams of intravenous risankizumab or placebo. After a follow-up of 12 weeks, they found that a greater proportion of the patients in the risankizumab group achieved clinical remission compared with those in the placebo group.

In the maintenance trial, the researchers assigned 548 patients to receive 180 or 360 milligrams of subcutaneous risankizumab or placebo. The patients who received 180 milligrams of risankizumab had higher clinical remission rates compared with those who received 360 milligrams of the drug; however, both groups achieved greater clinical remission compared with the placebo group.

The researchers concluded that longer-term studies will be needed to determine the benefits of risankizumab beyond 52 weeks.

Read more: JAMA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.